### RECEIVED CENTRAL FAX CENTER

SEP 2 1 2004

### Procter & Gamble - I.P. Division

#### IMPORTANT CONFIDENTIALITY NOTICE

The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone (collect) to arrange for return of the telecopied document to us.

# **FACSIMILE TRANSMITTAL SHEET AND** CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8

TO: United States Patent and Trademark Office

Fax No. 703-872-9306

I hereby certify that this correspondence is being facsimile transmitted to the United States

Selflender 21, 2004, to the above-identified Patent and Trademark Office on

Signature)

FROM: Kenva T. Pierre (Typed or printed name of person signing Certificate)

Fax No. 513-626-1355

Phone No. 513-626-4055

Application Information:

facsimile number.

inventor(s): Bowens-Jones et al.

S.N.:

10/719,755

Filed:

11/21/2003

Conf. No.:

3138

Case:

9447

Listed below are the item(s) being submitted with this Certificate of Transmission:\*\*

- Information Disclosure Statement, and one Copy for authorization to charge fees to Deposit Account
- PTO-SB08

Number of Pages (ncluding this Page: 8

5136261355 P.02/08

SEP 2 1 2004

P&G Case 9447

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of

A. D. Bowens-Jones et al.

Confirmation No. 3138

Serial No. 10/719,755

Group Art Unit 1617

Filed 11/21/2003

Examiner

For Antiperspirant Methods and Compositions

### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. [] 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

# 2. [X] 37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

# 3. [] 37 C.F.R. §1.97(h)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

# 4. [] 37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., Ex parte Quayle) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case). This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

Customer No. 27752

3

## ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

[]	(1)	In accordance with 37 C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign
paten	t docu	ments and non-patent literature.
		OR
[]	(2)	All of the cited references were previously cited by or submitted to the USPTO in prior
appli	cation	Case No, U.S. Patent Application Serial No, filed Applicants claim priority
		lication under 35 U.S.C. §120. Accordingly, copies of previously submitted references
are n	ot prov	vided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that
the ci	ited do	currents be carefully considered by the Examiner and made of record in this case.
		OR
[]	(3)	Copies of all said documents, except Cite Numbers, were submitted and
consi	dered	in parent application U.S. Patent Application Serial No, filed
Appli	icant(s	) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of
previ	ously :	submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d).
Copie	es of n	eferences not previously submitted are enclosed. It is respectfully requested that the cited
docu	ments	be carefully considered by the Examiner and made of record in this case.
rı		
LJ	(4)	Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited
refere	ince th	at is not in the English language is provided.
Гī		
LJ	(5)	Applicants also respectfully request the Examiner to consider and make of record the
co-pe	nding	applications listed on the attached page.
۲٦		
LJ	٠	Additional information is attached,
		Respectfully submitted,
		Kenya R Pierre
		Attorney for Applicant(s)
		Registration No. 50,165 (513) 626-4055
S	Spu	1/2/2 2004

Please type a plus sign (+) inside this box  $\rightarrow$  [+]

PTO/\$B08A (08-03)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE d to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO	COMPLETE IF KNOWN		
	Application Number	10/719,755	
INFORMATION DISCLOSURE	Confirmation Number	3138	
STATEMENT BY APPLICANT	Filing Date	-11/21/2003	
(use as many shects as necessary)	First Named Inventor	A. D. Bowens-Jones et al.	

SHEET 1 of 1

Group Art Unit 1617 Examiner Name 9447 Attorney Docket Number

### **U. S. PATENT DOCUMENTS**

EXAMINER INITIALS*	Citte No.1	DOCUMENT NUMBER  Number - Kind Code <sup>2</sup> (#known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Decument	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	01	4963591	10/16/1990	Fourman et al.	
	02	5508024A	04-16-1996	Tranner	
•	03	5593663A	01-14-1997	Leng et al.	
	04	5700455A	12-23-1997	Hinterwaldner et al.	
	05	5869600A	02-09-1999	Causton et al.	
<del></del>	08	5948882A	09-07-1999	Causton et al.	
	07	6274127B1	08-14-2001	Schraer et al.	
	08	6387356	05/14/2002	Csemica et al.	
	09	8720 Pub.	07/03/2003	Wyat et al.	
				<del></del>	
	-				
			•		
	1			l	l

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.1	FOREIGN PAT	CUMENT Kind Code <sup>a</sup> (If known)	Publication Date MM-DD-YYYY	Name of Patentse or Applicant of Cited Document	Pages, Cotumns, Lines Where Relevant Passages or Relevant Figures Appear	74
01,100			_1				
				<del></del>			
			 	<del></del>			
EXAMINER	t		 		DATE CONSIDERED	<u></u>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

EXAMINER: Initial if reference considered, whether or not classes is in contaminate with MPEP dos. Draw line unough classes in the interest and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kind Codes of U.S. Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08 (Revised for P&G use 10/8/2003)